American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting最新文献_第2页

Capturing Unicorns: Targeting Cancers With TP53 Mutations, RAS Alterations Beyond G12C, and MTAP Loss-No Target Is Out of the Realm of Possibility. 捕获独角兽：靶向癌症与TP53突变，RAS改变超越G12C，和MTAP丢失-没有目标是不可能的领域。

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting Pub Date : 2025-06-01 Epub Date: 2025-05-28 DOI: 10.1200/EDBK-25-473616

Pooja A Shah, Klas G Wiman, Karen Cichowski, Jordi Rodon Ahnert

{"title":"Capturing Unicorns: Targeting Cancers With TP53 Mutations, RAS Alterations Beyond G12C, and MTAP Loss-No Target Is Out of the Realm of Possibility.","authors":"Pooja A Shah, Klas G Wiman, Karen Cichowski, Jordi Rodon Ahnert","doi":"10.1200/EDBK-25-473616","DOIUrl":"https://doi.org/10.1200/EDBK-25-473616","url":null,"abstract":"In cancer genomics, there is the realization that some very frequently mutated genes like TP53 or KRAS are extremely hard to approach from a therapeutic perspective. In the realm of cancer treatment, the development of agents capable of transforming these alterations into actionable targets would be like capturing unicorns. These unicorns of oncology-drugs targeting undruggable targets that span various cancer types-offer an exciting opportunity for the development of histology-agnostic therapies. Among these, recent developments in targeting TP53 mutations, KRAS alterations, and MTAP loss mark pivotal advancements for innovative treatment strategies. TP53 mutations, which occur in nearly every cancer type, are central to tumorigenesis and contribute to resistance against conventional therapies. KRAS mutations, especially in cancers like pancreatic and lung cancers, are notoriously difficult to target but are now yielding promising therapeutic avenues. Similarly, MTAP is frequently deleted in cancers such as lung, pancreatic, and mesothelioma and plays a critical role in cellular metabolism and epigenetics, making its loss a significant vulnerability in tumor cells. Recent developments in drug discovery provide a broad foundation for the clinical testing of drugs that target common mechanisms across diverse tumor types, offering hope for a more universal approach to cancer treatment.","PeriodicalId":37969,"journal":{"name":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","volume":"45 3","pages":"e473616"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144175173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Moving Away From Standard Induction in Newly Diagnosed Acute Myeloid Leukemia. 在新诊断的急性髓性白血病中远离标准诱导。

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting Pub Date : 2025-06-01 Epub Date: 2025-06-03 DOI: 10.1200/EDBK-25-473646

Maire Okoniewski, Jesus Gonzalez Lugo, Tara L Lin

引用次数: 0

Breast and Gynecologic Cancer Care for Sexual Minority Women and Transgender People. 性少数妇女和变性人的乳腺癌和妇科癌症护理。

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting Pub Date : 2025-06-01 Epub Date: 2025-06-04 DOI: 10.1200/EDBK-25-473608

Gabrielle Mayer, Alberto Giovanni Leone, Olivia Korostoff-Larsson, Madeline Xin, Flora Cohen, Shail Maingi, Alison May Berner

{"title":"Breast and Gynecologic Cancer Care for Sexual Minority Women and Transgender People.","authors":"Gabrielle Mayer, Alberto Giovanni Leone, Olivia Korostoff-Larsson, Madeline Xin, Flora Cohen, Shail Maingi, Alison May Berner","doi":"10.1200/EDBK-25-473608","DOIUrl":"https://doi.org/10.1200/EDBK-25-473608","url":null,"abstract":"Sexual and gender minority (SGM) individuals continue to experience disparities in cancer risk, screening, treatment, and outcomes. Despite advances following the 2017 ASCO recommendations, inequities persist, driven by systemic barriers, stigma, and discrimination in health care. State-level and federal-level actions threaten health care access to for sexual minority women (SMW) and transgender and gender-diverse (TGD) people creating additional barriers to safe and evidence-based health care. This review outlines the literature and gives practical recommendations for breast and gynecologic cancer care of SMW and TGD people. SMW and transgender men and nonbinary people with a cervix share multiple barriers to cervical cancer screening with lower uptake. TGD individuals face additional barriers, including gender dysphoria during examinations. Current evidence supports offering human papilloma virus self-sampling to improve screening uptake. Evidence supports lower breast cancer risk in TGD people compared with cisgender women but advice must be tailored to surgical history and hormone use. For TGD individuals with cancer, gender-affirming hormone therapy should be managed through shared decision making, balancing oncologic risk with quality-of-life considerations. Cancer care must account for the unique needs of SGM populations, emphasizing cultural humility, structural competency, and trauma-informed care. While broader health care reforms are needed to address the systemic inequities that underlie these disparities, clinicians have an obligation to provide affirming, patient-centered care that recognizes the impact of societal discrimination on health and fosters trust with SGM patients.","PeriodicalId":37969,"journal":{"name":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","volume":"45 3","pages":"e473608"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144227054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Speaking to Power With Power: Advocating for Your Profession. 用权力说话：倡导你的职业。

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting Pub Date : 2025-06-01 Epub Date: 2025-06-10 DOI: 10.1200/EDBK-25-471872

Martin Palmeri, Eric J McNulty, Alti Rahman, Jason Westin

{"title":"Speaking to Power With Power: Advocating for Your Profession.","authors":"Martin Palmeri, Eric J McNulty, Alti Rahman, Jason Westin","doi":"10.1200/EDBK-25-471872","DOIUrl":"https://doi.org/10.1200/EDBK-25-471872","url":null,"abstract":"Patient-centered physician-directed care is facing unprecedented challenges. Escalating health care spending on low-value services with a focus on managing disease rather than promoting health is leading to increasing financial toxicity to patients and payment pushback by insurers. In an effort to rein in costs, policymakers are implementing legislation and regulations aimed at curbing spending that have had the unintentional consequences of increasing market consolidations, ultimately creating monopolies and monopsonies that have driven up costs, lowered quality, and ultimately disenfranchises both doctors and patients. The ramifications of such policies have opened the floodgates to the corporatization of medicine. \"Speaking to Power With Power: Advocating for Your Profession\" explores how physicians can become agents of change in this ever-evolving health care paradigm. This session is geared to exploring the challenges our profession faces and how oncologists can advocate for their patients and profession in their communities, practices, and hospitals both locally and on the state and national arenas. Topics for discussion will include: Leading in your community: explore the challenges facing doctors in their practices and institutions and how they can lead on the local level. Advocating for change: introduction to advocacy tools that can be used on the state and national levels. Negotiating your path to career success: provides tools physicians can use to find common ground when negotiating with key stakeholders. Engaging in payer contracting: how to navigate the ever-changing payer contracting marketplace and leverage value propositions and networks with payers.","PeriodicalId":37969,"journal":{"name":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","volume":"45 3","pages":"e471872"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144267526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Connecting Through Cancer: Overcoming Distress and Isolation Together. 通过癌症连接：一起克服痛苦和孤立。

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting Pub Date : 2025-06-01 Epub Date: 2025-06-16 DOI: 10.1200/EDBK-25-474562

Erin L Price, Shanda H Blackmon, Reshma Jagsi

引用次数: 0

Melanoma 3.0T-Tech Innovations, New Targeted Therapies, and T-Cell Breakthroughs. 黑色素瘤3.0技术创新，新的靶向治疗和t细胞突破。

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting Pub Date : 2025-06-01 Epub Date: 2025-07-09 DOI: 10.1200/EDBK-25-473120

Donald P Lawrence, Susan Swetter, Meredith McKean

{"title":"Melanoma 3.0T-Tech Innovations, New Targeted Therapies, and T-Cell Breakthroughs.","authors":"Donald P Lawrence, Susan Swetter, Meredith McKean","doi":"10.1200/EDBK-25-473120","DOIUrl":"https://doi.org/10.1200/EDBK-25-473120","url":null,"abstract":"New technologies and innovations are changing the future of melanoma care. Teledermatology and skin screening mobile apps aided by artificial intelligence (AI) diagnostic support could assist in closing disparity gaps in melanoma early detection and access to specialty care. Although the field of AI in dermatology has exploded over the past decade, prospective validation of available algorithms using real-world, multimodal data sets has shown performance decline, limiting their current use in clinical practice. Newer methodological approaches have focused on how AI can augment clinical decision making to speed diagnosis and care delivery-and whether the model output results in a favorable change for the patient. Selective BRAF and MEK inhibitors have an established role in the adjuvant and metastatic setting for the approximately 50% of patients whose melanomas harbor a BRAF V600 mutation. Acquired resistance to these agents remains a challenge, however. For other driver mutations, including class II and III BRAF mutations, alterations in NRAS and CDKN2A, novel agents and combinations are demonstrating promising activity. At least 50% of patients with metastatic melanoma do not derive long-term benefit from immune checkpoint inhibitors (ICIs). Adoptive cellular immunotherapy with tumor infiltrating lymphocytes offers the possibility of a durable response for a minority of these patients. Potentially more effective and better tolerated T-cell therapies are being evaluated in clinical trials.","PeriodicalId":37969,"journal":{"name":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","volume":"45 3","pages":"e473120"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144601828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bispecific Antibodies in Hematologic and Solid Tumors: Current Landscape and Therapeutic Advances. 血液学和实体肿瘤中的双特异性抗体：现状和治疗进展。

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting Pub Date : 2025-06-01 Epub Date: 2025-04-08 DOI: 10.1200/EDBK-25-473148

Lorenzo Guidi, Julian Etessami, Carmine Valenza, Augusto Valdivia, Funda Meric-Bernstam, Enriqueta Felip, Giuseppe Curigliano

{"title":"Bispecific Antibodies in Hematologic and Solid Tumors: Current Landscape and Therapeutic Advances.","authors":"Lorenzo Guidi, Julian Etessami, Carmine Valenza, Augusto Valdivia, Funda Meric-Bernstam, Enriqueta Felip, Giuseppe Curigliano","doi":"10.1200/EDBK-25-473148","DOIUrl":"https://doi.org/10.1200/EDBK-25-473148","url":null,"abstract":"Bispecific antibodies (bsAbs) have emerged as a novel class of therapeutics, offering a dual-targeting strategy to enhance the therapeutic efficacy of monoclonal antibodies, which is often limited by tumor heterogeneity and the occurrence of resistance mechanisms. By simultaneously engaging two distinct antigens or pathways, bsAbs disrupt multiple signaling cascades simultaneously, preventing escape mechanisms and offering a more durable response. Furthermore, they can optimize immune activation, improving immune cell recruitment strategies. In particular, T-cell engager bsAbs facilitate immune cell-mediated tumor destruction by linking T cells to tumor antigens. Instead, dual immune checkpoint inhibitors (CPIs) enhance immune activation by blocking inhibitory signals. Additionally, bsAbs targeting tumor growth factors or receptor tyrosine kinases offer solutions for overcoming drug resistance in solid tumors. Although bsAbs have shown remarkable success in hematologic malignancies, their expansion into solid tumors faces key challenges, including tumor heterogeneity, limited tumor penetration, and the risk of on-target, off-tumor toxicities. Addressing these challenges requires innovative engineering strategies, optimized delivery mechanisms, and careful patient selection to maximize therapeutic benefit while mitigating adverse effects. The efficacy of bsAbs in clinical trials has led to their approval for both hematologic and solid malignancies, with numerous agents in development. Combination strategies with chemotherapy, targeted agents, and immune CPIs could represent a promising strategy to further expand their potential. As research progresses, bsAbs are expected to play a role in reshaping the future of precision oncology, offering more effective and tailored treatment options.","PeriodicalId":37969,"journal":{"name":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","volume":"45 3","pages":"e473148"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143812536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Navigating Early Career as an Oncologist: Thriving in Diverse Paths. 作为肿瘤学家的早期职业生涯：在不同的道路上茁壮成长。

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting Pub Date : 2025-06-01 Epub Date: 2025-05-05 DOI: 10.1200/EDBK-25-481834

Gita Suneja, Marjorie C Green, Janaki Parameswaran, Joseph W McCollom

{"title":"Navigating Early Career as an Oncologist: Thriving in Diverse Paths.","authors":"Gita Suneja, Marjorie C Green, Janaki Parameswaran, Joseph W McCollom","doi":"10.1200/EDBK-25-481834","DOIUrl":"https://doi.org/10.1200/EDBK-25-481834","url":null,"abstract":"Early-career oncologists navigate a complex landscape of professional development, clinical responsibilities, and research endeavors. This manuscript explores key challenges and strategies for success in the early years of an oncology career, focusing on the first job after fellowship, career transitions, and practical tips for intentionality. Effective mentorship is pivotal, providing guidance in clinical decision making, research pursuits, and professional networking. Career development strategies include securing funding, building collaborative networks, and identifying opportunities for leadership. Additionally, balancing clinical duties with research and personal well-being requires time management and institutional support. This article emphasizes the importance of fostering inclusive mentorship, advocating for work-life integration, and leveraging institutional and professional resources to support career sustainability. By addressing these key aspects, early-career oncologists can build a fulfilling and impactful career while contributing meaningfully to the field of oncology.","PeriodicalId":37969,"journal":{"name":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","volume":"45 3","pages":"e481834"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144019116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Redefining Survivorship in Pediatric Oncology: A Fresh Look at a Long-Term Problem. 重新定义儿童肿瘤的生存期：一个长期问题的新视角。

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting Pub Date : 2025-06-01 Epub Date: 2025-04-11 DOI: 10.1200/EDBK-25-472780

Saro H Armenian, Leontien Kremer, Emily S Tonorezos, Smita Bhatia

{"title":"Redefining Survivorship in Pediatric Oncology: A Fresh Look at a Long-Term Problem.","authors":"Saro H Armenian, Leontien Kremer, Emily S Tonorezos, Smita Bhatia","doi":"10.1200/EDBK-25-472780","DOIUrl":"https://doi.org/10.1200/EDBK-25-472780","url":null,"abstract":"Therapeutic advances have resulted in a growing population of childhood cancer survivors. Unfortunately, this success comes at a price. A substantial proportion of the survivors develop life-threatening chronic health conditions such as subsequent neoplasms and cardiovascular diseases. These conditions are likely initiated by exposure to chemotherapy and radiation used to treat the underlying childhood cancer and potentiated by additional accumulation of comorbidities. These conditions can cause premature death, resulting in significantly shorter lifespans. Previous research using large cohorts of childhood cancer survivors has described the magnitude of the burden or morbidity and the association between key therapeutic exposures and specific chronic health conditions. These findings have resulted in the creation of risk-based guidelines for surveillance and early detection of the complications. Now, research is increasingly focused on understanding the pathogenesis of treatment-related complications, identifying survivors at risk for these complications, developing targeted interventions, determining where and how to provide life-long risk-based care, and finally, whether providing risk-based surveillance will mitigate the burden of morbidity and mortality among childhood cancer survivors. We address these topics in this manuscript.","PeriodicalId":37969,"journal":{"name":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","volume":"45 3","pages":"e472780"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144048591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Which Is the Best Tyrosine Kinase Inhibitor for Newly Diagnosed Chronic Myelogenous Leukemia? 哪种酪氨酸激酶抑制剂是治疗新诊断的慢性粒细胞白血病的最佳药物？

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting Pub Date : 2025-06-01 Epub Date: 2025-04-24 DOI: 10.1200/EDBK-25-473082

Naranie Shanmuganathan, Michael Osborn, Timothy P Hughes

{"title":"Which Is the Best Tyrosine Kinase Inhibitor for Newly Diagnosed Chronic Myelogenous Leukemia?","authors":"Naranie Shanmuganathan, Michael Osborn, Timothy P Hughes","doi":"10.1200/EDBK-25-473082","DOIUrl":"https://doi.org/10.1200/EDBK-25-473082","url":null,"abstract":"The choice of frontline therapy for a patient with chronic phase chronic myeloid leukemia (CP-CML) can have a profound effect on the long-term clinical outcome. Currently, five tyrosine kinase inhibitors (TKIs-imatinib, dasatinib, nilotinib, bosutinib, and asciminib) are available for frontline therapy, but no single TKI is optimal for all patients. EUTOS long-term survival (ELTS) risk score, comorbidities, and treatment-free remission (TFR) priority are the key determinants of frontline TKI selection. Higher ELTS score, low age and comorbidity score, and a high priority for achievement of TFR would all favor the frontline use of a more potent TKI than imatinib. However, no TKI has improved survival compared with imatinib. In children with CP-CML, imatinib, dasatinib, and nilotinib have similar long-term efficacy, with ease of administration and impact of toxicities on quality of life being key considerations. Recent adult trials of reduced-dose dasatinib frontline showed that efficacy may be equivalent to standard-dose dasatinib with a better tolerability and safety profile, but experience is limited in patients with high-risk ELTS scores. The ASC4FIRST trial has confirmed that tolerability and molecular response with asciminib are superior to those with both imatinib and the second-generation (2G)-TKIs. While the overall treatment failure rate was lower with asciminib, the rate of BCR::ABL1 mutations that emerged with asciminib appeared to be higher. The risk of emergent mutations appears to be highly associated with the presence of ASXL1 mutations in the CML cells at diagnosis, but more work is needed to understand the implications of this finding.","PeriodicalId":37969,"journal":{"name":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","volume":"45 3","pages":"e473082"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144022622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0